Literature DB >> 27076125

Principles of Vaccination.

Fred Zepp1.   

Abstract

While many of the currently available vaccines have been developed empirically, with limited understanding on how they activate the immune system and elicit protective immunity, the recent progress in basic sciences like immunology, microbiology, genetics, and molecular biology has fostered our understanding on the interaction of microorganisms with the human immune system. In consequence, modern vaccine development strongly builds on the precise knowledge of the biology of microbial pathogens, their interaction with the human immune system, as well as their capacity to counteract and evade innate and adaptive immune mechanisms. Strategies engaged by pathogens strongly determine how a vaccine should be formulated to evoke potent and efficient protective immune responses. The improved knowledge of immune response mechanisms has facilitated the development of new vaccines with the capacity to defend against challenging pathogens and can help to protect individuals particular at risk like immunocompromised and elderly populations. Modern vaccine development technologies include the production of highly purified antigens that provide a lower reactogenicity and higher safety profile than the traditional empirically developed vaccines. Attempts to improve vaccine antigen purity, however, may result in impaired vaccine immunogenicity. Some of such disadvantages related to highly purified and/or genetically engineered vaccines yet can be overcome by innovative technologies, such as live vector vaccines, and DNA or RNA vaccines. Moreover, recent years have witnessed the development of novel adjuvant formulations that specifically focus on the augmentation and/or control of the interplay between innate and adaptive immune systems as well as the function of antigen-presenting cells. Finally, vaccine design has become more tailored, and in turn has opened up the potential of extending its application to hitherto not accessible complex microbial pathogens plus providing new immunotherapies to tackle diseases such as cancer, Alzheimer's disease, and autoimmune disease. This chapter gives an overview of the key considerations and processes involved in vaccine development. It also describes the basic principles of normal immune respoinses and its their function in defense of infectious agents by vaccination.

Entities:  

Keywords:  B cell; Immunology; Infectious disease; Pathogen; T cell; Vaccination; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 27076125     DOI: 10.1007/978-1-4939-3387-7_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  MSU Crystals Enhance TDB-Mediated Inflammatory Macrophage IL-1β Secretion.

Authors:  Kanu Wahi; Kristel Kodar; Melanie J McConnell; Jacquie L Harper; Mattie S M Timmer; Bridget L Stocker
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

2.  Revisiting the Principles of Designing a Vaccine.

Authors:  Shubhranshu Zutshi; Sunil Kumar; Prashant Chauhan; Bhaskar Saha
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change.

Authors:  Tamas Fulop; Anis Larbi; Graham Pawelec; Alan A Cohen; Guillaume Provost; Abedelouahed Khalil; Guy Lacombe; Serafim Rodrigues; Mathieu Desroches; Katsuiku Hirokawa; Claudio Franceschi; Jacek M Witkowski
Journal:  Vaccines (Basel)       Date:  2022-04-13

4.  Sm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons.

Authors:  Juan U Rojo; Michael W Melkus; Kameswara Rao Kottapalli; Oscar E Okiya; Justin Sudduth; Weidong Zhang; Adebayo J Molehin; Darrick Carter; Afzal A Siddiqui
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

5.  Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.

Authors:  Raymond Chang; Wei-Zen Sun
Journal:  Drug Discov Today       Date:  2020-07-03       Impact factor: 7.851

6.  A novel strategy for developing vaccine candidate against Jaagsiekte sheep retrovirus from the envelope and gag proteins: an in-silico approach.

Authors:  Nuha Amin Mahmoud; Abdelmajeed M Elshafei; Yassir A Almofti
Journal:  BMC Vet Res       Date:  2022-09-10       Impact factor: 2.792

Review 7.  Use of Protamine in Nanopharmaceuticals-A Review.

Authors:  Ivana Ruseska; Katja Fresacher; Christina Petschacher; Andreas Zimmer
Journal:  Nanomaterials (Basel)       Date:  2021-06-07       Impact factor: 5.076

8.  Vaccine design based on 16 epitopes of SARS-CoV-2 spike protein.

Authors:  Jinlei He; Fan Huang; Jianhui Zhang; Qiwei Chen; Zhiwan Zheng; Qi Zhou; Dali Chen; Jiao Li; Jianping Chen
Journal:  J Med Virol       Date:  2020-11-01       Impact factor: 20.693

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.